Cytimm Therapeutics is a clinical-stage biopharmaceutical company located in San Diego. We are focusing on the development of innovative IL-2 based therapies with First-In-Class potential for cancer, neurodegenerative and autoimmune diseases. Cytimm uses innovative technologies to decouple the two opposite functions of IL-2 and developed two proprietary IL-2 based drugs, CTM103 and CTM201, each targets a spectrum of diseases: CTM103 targets solid tumors including Lung Cancer, Melanoma, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Colon Cancer, Bladder Cancer; CTM201 targets Systemic lupus erythematosus (SLE), Psoriasis, Ulcerative Colitis (UC), Atopic Dermatitis, Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson's disease. These two “pipeline-in-a-product” assets have the potential to make tremendous impacts, both socially and commercially.